ryavisc is contraindicated in patients with known hypersensitivity to hyaluronate preparations or in cases of present infections or skin diseases in the area of the injection site. Use caution when injecting ryavisc into patients who are allergic to avian proteins, feathers, and egg products.
The safety and effectiveness of ryavisc has not been established in children or in pregnant or lactating women, for use in other joints or for concomitant use with other injectable. It is unknown whether ryavisc is excreted in human milk. The effectiveness of a single treatment cycle of less than 3 injections has not been established.
Transient increases in inflammation in the injected knee following ryavisc injection have been reported in some patients with inflammatory arthritis and should not be injected if objective signs of inflammation are present. Transient pain and/or swelling of the injected joint may occur after intra-articular injection of ryavisc Anaphylactic and allergic reactions have been reported with the use of this product.
